Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Myelodysplastic Syndrome
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: I. To assess the clinical activity of canakinumab in patients with low or intermediate-1 myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). SECONDARY OBJECTIVES: I. To study the safety profile of canakinumab in patients with low or intermediate-1 MDS or CMML...
PRIMARY OBJECTIVE: I. To assess the clinical activity of canakinumab in patients with low or intermediate-1 myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). SECONDARY OBJECTIVES: I. To study the safety profile of canakinumab in patients with low or intermediate-1 MDS or CMML. II. Rate of transfusion independence. III. Duration of response. IV. Progression-free survival (PFS), leukemia-free survival (LFS) and overall survival (OS). EXPLORATORY OBJECTIVE: I. Correlative studies (pharmacodynamic [PD] parameters of canakinumab). OUTLINE: Patients receive canakinumab subcutaneously (SC) on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 6 months thereafter.
Tracking Information
- NCT #
- NCT04239157
- Collaborators
- National Cancer Institute (NCI)
- Novartis
- Investigators
- Principal Investigator: Guillermo Garcia-Manero M.D. Anderson Cancer Center